TickerFacts.

Transcode Therapeutics, Inc. (RNAZ): Capital Expenditures

Annual figures by period end, from SEC filings.

$6.7K
Year ended 2025-12-31
-59.6%
3-year compound annual growth
$254.8K2021-12-31: $254.8K2022-12-31: $100.9K2023-12-31: $35.6K2024-12-31: $21.8K2025-12-31: $6.7K$6.7K
2021-12-31 Capital Expenditures (USD) 2025-12-31
Period endedCapital ExpendituresChange YoYSource filing
2025-12-31$6.7K-69.4%2026-04-15, From 2025-01-01
2024-12-31$21.8K-38.9%2026-04-15, From 2024-01-01
2023-12-31$35.6K-64.7%2025-04-15, From 2023-01-01
2022-12-31$100.9K-60.4%2024-04-01, From 2022-01-01
2021-12-31$254.8Kn/a2023-03-31, From 2021-01-01

Capital Expenditures at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedCapital ExpendituresChange YoY
Transcode Therapeutics, Inc. (RNAZ)2025-12-31$6.7K-69.4%
Apimeds Pharmaceuticals US, Inc. (APUS)2025-12-31$57.3Kn/a
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$111.0K-8.3%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$562.0K+253.5%
Gyre Therapeutics, Inc. (GYRE)2025-12-31$1.19M-48.6%
Climb Bio, Inc. (CLYM)2025-12-31$186.0Kn/a
Boundless Bio, Inc. (BOLD)2025-12-31$546.0K-78.5%
Corbus Pharmaceuticals Holdings, Inc. (CRBP)2025-12-31$7.0Kn/a
Precigen, Inc. (PGEN)2025-12-31$2.00M-76.8%

Compare RNAZ, APUS, ACRS, AQST side by side · Screen every company in Pharmaceutical Preparations ↗